Life science market intelligence company, Evaluate Ltd, today announced
the appointment of Alex Karle to the role of Chief Executive Officer. Dr
Jonathan de Pass, founder and Chief Executive Officer for the last 18
years will become Chairman of the Board. These appointments are
Since founding Evaluate in March 1996, Dr de Pass has overseen the
development of the company into a world leader in market intelligence
and analysis for the life science sector. Over the years Evaluate has
created many new industry standards for forecasting global drug sales
and other industry performance metrics resulting in uninterrupted sales
growth compounding at 20 percent per annum over the last 10 years.
As Chief Operating Officer, Mr Karle has been responsible for sales,
marketing and business development for Evaluate, and the creation of new
products and software capabilities. Since joining Evaluate in 2012 as
Chief Operating Officer, he has played a critical role in the launch of
EvaluateMedTech, setting a new standard in integrated analysis and
consensus forecasts for the medical device and diagnostic industry.
Prior to his role at Evaluate, Mr Karle served as Vice President,
Strategy & Development of IP & Science at Thomson Reuters. Mr Karle
began his career as a Senior Associate at Booz Allen & Hamilton. He
holds an MBA from Yale University and a BA in Business, Economics and
Law from the European Business Programme in Germany.
"It's been an absolute privilege and a joy working with so many talented
colleagues and clients over the years" said Dr de Pass. "Together we
have built an exceptional business that is trusted by a blue chip client
base of major companies and institutions from around the world".
He added, "It's now time to hand the reins over to Alex. Under his
leadership and supported by a first class team, I'm confident that
Evaluate is i excellent hands and will continue to develop its services
to provide ever more benefits for our clients. I congratulate Alex on
"With his drive and vision, Jonathan has created a world leading
organisation and he has set a very high standard. I am very much looking
forward to taking on the CEO position," said Mr Karle. "It is important
to me that Jonathan will remain an integral part of the team as
Chairman. His knowledge and insight will be invaluable as we continue to
expand Evaluate's products and services in close partnership with our
clients across the Pharmaceutical and Medical Devices industry."
About Evaluate Ltd.
Evaluate is the trusted source for life science market intelligence and
analysis with exclusive consensus forecasts to 2020. Our services
include EvaluatePharma, EvaluateClinical
Trials and EvaluateMedTech.
Our award-winning editorial team, EP
Vantage, leverages our strategic analysis to cut through the noise,
giving you daily opinion and insights. The Evaluate services enable the
life science community to make sound business decisions about value and
opportunity. For more information please visit www.evaluategroup.com.
On Twitter: @evaluatepharma,
[ Back To NFVZone's Homepage ]